Sorin Sorin Draghici

US Patent:

7964536, Jun 21, 2011

Filed:

Feb 17, 2005

Appl. No.:

11/060867

Inventors:

Michael Tainsky - West Bloomfield MI, US
Sorin Draghici - Troy MI, US
Madhumita Chatterjee - Lake Orion MI, US

Assignee:

Wayne State University - Detroit MI

International Classification:

C40B 40/10
C07K 4/00
C07K 7/00
C07K 14/00
G01N 33/53

US Classification:

506 18, 435 71, 530300, 530324, 530327, 530328, 530329, 530330, 530350

Abstract:

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim , the software including analyzing means for analyzing the arrays.

US Patent:

8614169, Dec 24, 2013

Filed:

Feb 17, 2006

Appl. No.:

11/816471

Inventors:

Michael Tainsky - Southfield MI, US
Sorin Draghici - Plymouth MI, US
Madhumita Chatterjee - Lake Orion MI, US

Assignee:

Wayne State University - Detroit MI

International Classification:

C40B 30/04

US Classification:

506 9

Abstract:

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim 17, the software including analyzing means for analyzing the arrays.

US Patent:

20030071843, Apr 17, 2003

Filed:

Oct 17, 2001

Appl. No.:

09/981865

Inventors:

Bruce Hoff - Venice CA, US
Soheil Shams - Redondo Beach CA, US
Sorin Draghici - Detroit MI, US
Kiyoko Aoki - Playa del Rey CA, US

International Classification:

G09G005/00

US Classification:

345/763000, 345/835000, 345/769000

Abstract:

Systems and methods of analyzing data and for specifying and applying user-selected, user-variable sequences of mathematical data preparation operations to data and methods for normalizing data that include dividing the data into a plurality of groups where the number of groups is a function of the range and number of values and for calculating a normalization correction for each group are disclosed.

US Patent:

20040005556, Jan 8, 2004

Filed:

Dec 4, 2001

Appl. No.:

10/004587

Inventors:

Michael Tainsky - Detroit MI, US
Sorin Draghici - Detroit MI, US

International Classification:

C12Q001/68
G01N033/574
G06F019/00
G01N033/48
G01N033/50
C12M001/34

US Classification:

435/006000, 435/007230, 435/287200, 702/019000

Abstract:

There is provided a diagnostic tool for use in diagnosing diseases, the tool having a detector for detecting the presence of an array of markers indicative of disease. Also provided is a combination of markers for disease, the combination including at least two markers of the disease. A method of choosing such combinations of markers for a given disease as well as a method for detecting a combination of markers for diagnosing the presence of a disease state or determining a disease stage is also provided. The method includes selectively biopanning sera obtained from a patient to obtain cDNA clones to array for analysis and determining if the markers are present among the cDNA clones present in the disease. Epitopes found using this method are also provided as well as a database incorporating these epitopes. A biochip for detecting the presence of a disease marker in a patient's sera is provided, wherein the biochip has a detector contained within the biochip for detecting disease markers in a patient's sera.

US Patent:

20050250137, Nov 10, 2005

Filed:

Mar 21, 2005

Appl. No.:

11/085440

Inventors:

Michael Tainsky - West Bloomfield MI, US
Sorin Draghici - Troy MI, US
Olga Studitskaia - Edison NJ, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435006000, 702020000

Abstract:

A diagnostic tool for use in diagnosing diseases, the tool is a detector for detecting a presence of an array of markers being used to determine gene expression changes that are related to cellular immortalization, the presence of the markers being indicative of a specific disease and the markers and treatments found by the tool. A tool for interpreting results of a microarray, wherein the tool is a computer program for analyzing the results of microrarrays. A method of creating an array of markers for diagnosing the presence of disease by microarraying sera obtained from a patient to obtain molecular markers of disease and detecting markers that are present only in the sera of patients with a specific disease thereby detecting molecular markers being used to determine gene expression changes that are related to cellular immortalization and for use in diagnosing disease.

US Patent:

20080267999, Oct 30, 2008

Filed:

Sep 21, 2007

Appl. No.:

11/903312

Inventors:

Michael A. Tainsky - West Bloomfield MI, US
Sorin Draghici - Troy MI, US
Ho-Sheng Lin - Plymouth MI, US

International Classification:

A61K 39/12
C12M 1/00
C40B 60/10
C12Q 1/02
C12Q 1/68
A61P 19/00
C40B 50/06
G01N 33/574
G01N 33/53

US Classification:

4242771, 4352872, 506 38, 435 29, 435 723, 435 792, 506 26, 435 6

Abstract:

A diagnostic device for and method of detecting the presence of head and neck squamous cell carcinoma (HNSCC) in a patient including a detector device for detecting a presence of at least one marker indicative of HNSCC, the detector device including a panel of markers for HNSCC. A diagnostic device for and method of staging HNSCC in a patient including a detector device for detecting a presence of at least one marker indicative of stages of HNSCC, the detector device including a panel of markers for HNSCC. Markers for head and neck squamous cell carcinoma selected from the markers listed in Table 5. Methods of personalized immunotherapy, making a personalized anti-cancer vaccine, and predicting a clinical outcome in a HNSCC patient. A method of making a panel of HNSCC markers.

US Patent:

20090182513, Jul 16, 2009

Filed:

Jul 25, 2008

Appl. No.:

12/180303

Inventors:

Sorin Draghici - Detroit MI, US

Assignee:

Wayne State University - Detroit MI

International Classification:

G06F 19/00
G01N 33/48
G06F 17/18

US Classification:

702 19, 702181

Abstract:

Methods and systems for predicting the significance of a biological pathway in a disease state, the method and system comprising: (a) providing data on the expression levels of a plurality of biomolecules differentially expressed in a disease state as compared with the same biomolecules expressed in a non-diseased state within the pathway: (b) determining the probability of the presence of the plurality of biomolecules in said diseased state; (c) determining the effect of each biomolecule from the plurality of biomolecules on the expression of different downstream biomolecules within the pathway thereby providing a perturbation factor for each biomolecule in the pathway; (d) combining the statistical significance of the differentially expressed biomolecule within the pathway present in the disease state with a sum of perturbation factors for all of the biomolecules in the pathway to generate an impact factor for the pathway relevant to the disease state; (e) calculating the statistical significance of the impact factor based upon a determined probability of having a statistical significant presence of differentially expressed biomolecules in step (b) and the sum of perturbation factors within the pathway in step (c); and (f) outputting the statistical significance of the impact factor for the pathway relevant to the disease for a user.

US Patent:

20110190149, Aug 4, 2011

Filed:

Jul 23, 2010

Appl. No.:

12/824305

Inventors:

Michael Tainsky - West Bloomfield MI, US
Sorin Draghici - Troy MI, US
Madhumita Chatterjee - Lake Orion MI, US

International Classification:

C40B 30/04
G01N 30/96
C40B 40/00
G01N 33/53
C40B 40/10
C07K 16/00
C07K 14/00

US Classification:

506 9, 422 69, 506 13, 436501, 506 18, 5303873, 530350

Abstract:

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.